Business description: Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Number of employees: 8

Sales by Activity: Seelos Therapeutics, Inc.

Fiscal Period: December 2019 (USD) 2020 (USD) 2021 (USD) 2022 (USD) 2023 (USD)

Pharmaceuticals

375K - - - 2.2M

Geographical breakdown of sales: Seelos Therapeutics, Inc.

Fiscal Period: December 2019 (USD) 2020 (USD) 2021 (USD) 2022 (USD) 2023 (USD)

United States

375K - - - 2.2M

Executive Committee: Seelos Therapeutics, Inc.

Manager TitleAgeSince
Chief Executive Officer 66 01/01/2019
Director of Finance/CFO 54 01/09/2021
Chief Tech/Sci/R&D Officer - -
Investor Relations Contact - 01/01/2019

Company details: Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc.

300 Park Avenue

10022, New York

+

http://www.seelostherapeutics.com
address Seelos Therapeutics, Inc.(SEELQ)

Bio Therapeutic Drugs

Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1
+0.34%+1.12%+34.75%+61.06% 64.38B
+0.42%+3.68%+15.46%+85.41% 56.16B
+0.87%+2.28%+15.72%+107.45% 54.16B
-2.06%-3.20%+24.93%+52.65% 45.33B
+0.01%-2.01%+20.05%+98.29% 42.25B
-1.03%+0.48%+219.14%+923.87% 40.78B
+1.69%+46.03%+109.89%+93.92% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average -0.13%+3.85%+52.68%+161.77% 39.27B
Weighted average by Cap. -0.04%+3.36%+49.66%+160.73%
  1. Stock Market
  2. Stocks
  3. SEELQ Stock
  4. Company Seelos Therapeutics, Inc.